petosemtamab
merus
['mcla-158', 'solid tumor']
fascinating findings at #aacr23 from of on the clinical activity of mcla-158 in advanced hnscc. for more on bispecifics, view this #jitc phase i study of a mesothelin-cd40 bispecific in pts with advanced solid tumors from 
The official journal of @SITCancer, covering all aspects of tumor immunology and cancer immunotherapy. #JITC Interim Editor-in-Chief: James L. Gulley (@gulley1)